An umbrella review and quality assessment of renin-angiotensin system drugs use and COVID-19 outcomes: what is the quality of the research evidence?

Natalie Mcfadyen Weir; Tanja Mueller; Amanj Kurdi

doi:10.1016/j.sapharm.2023.09.025

An umbrella review and quality assessment of renin-angiotensin system drugs use and COVID-19 outcomes: what is the quality of the research evidence?

Natalie Mcfadyen Weir, Tanja Mueller, Amanj Kurdi

Research output: Contribution to journal › Conference abstract › peer-review

Original language	English
Article number	B8
Pages (from-to)	219
Number of pages	1
Journal	Research in Social and Administrative Pharmacy
Volume	20
Issue number	2
Early online date	11 Jan 2024
DOIs	https://doi.org/10.1016/j.sapharm.2023.09.025
Publication status	Published - Feb 2024
Event	Nordic Social Pharmacy Conference 2023 - The Arctic University of Norway, Norway Duration: 7 Jun 2023 → 9 Jun 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.sapharm.2023.09.025

Cite this

@article{99cd13d79c7e427fba87abf8ee8b612f,

title = "An umbrella review and quality assessment of renin-angiotensin system drugs use and COVID-19 outcomes: what is the quality of the research evidence?",

author = "Weir, {Natalie Mcfadyen} and Tanja Mueller and Amanj Kurdi",

year = "2024",

month = feb,

doi = "10.1016/j.sapharm.2023.09.025",

language = "English",

volume = "20",

pages = "219",

journal = "Research in Social and Administrative Pharmacy",

issn = "1551-7411",

publisher = "Elsevier Inc.",

number = "2",

note = "Nordic Social Pharmacy Conference 2023 ; Conference date: 07-06-2023 Through 09-06-2023",